We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-Term Remission of Primary Bone Marrow Diffuse Large B-Cell Lymphoma Treated with High-Dose Chemotherapy Rescued by In Vivo Rituximab-Purged Autologous Stem Cells.
- Authors
Kazama, Hiroshi; Teramura, Masanao; Yoshinaga, Kentaro; Masuda, Akihiro; Motoji, Toshiko
- Abstract
Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is a rare type of extranodal lymphoma with poor prognosis. Here, we report a case of primary bone marrow DLBCL successfully treated with high-dose chemotherapy and rescued by in vivo rituximab-purged autologous stem cells. A 39-year-old woman visited our hospital because of anemia. Bone marrow examination revealed a large B-cell lymphoma invasion. An 18F-fluorodeoxyglucose positron emission tomography scan revealed disseminated bone marrow uptake without evidence of dissemination at other sites. These findings led to a diagnosis of primary bone marrow DLBCL. Our patient underwent R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and achieved complete remission. Subsequently, she received high-dose chemotherapy with an in vivo rituximab-purged autologous stem cell transplant. Seven years have passed since the transplantation, and she remains in remission. This suggests that transplantation of an in vivo rituximab-purged autograft is a promising strategy for primary bone marrow DLBCL.
- Subjects
LYMPHOMA treatment; BONE marrow diseases; DISEASE remission; PRIMARY care; B cells; STEM cell transplantation; DRUG therapy
- Publication
Case Reports in Medicine, 2012, p1
- ISSN
1687-9627
- Publication type
Article
- DOI
10.1155/2012/957063